Clinical Trials Directory

Trials / Completed

CompletedNCT00325130

Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)

An Open-Label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of V501 Given Concomitantly With Menactra™ and ADACEL™ in Healthy Adolescents 11-17 Years of Age

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
1,042 (actual)
Sponsor
Merck Sharp & Dohme LLC · Industry
Sex
All
Age
11 Years – 17 Years
Healthy volunteers
Accepted

Summary

Data from this study are expected to demonstrate that V501 (Human Papillomavirus (HPV) \[Types 6, 11, 16, 18\] Recombinant Vaccine) , when administered concomitantly with a combined diphtheria, tetanus, pertussis (Tdap) vaccine and a meningococcal conjugate vaccine in adolescents remains immunogenic and well-tolerated and it does not impair the immunogenicity of the concomitant vaccines.

Conditions

Interventions

TypeNameDescription
BIOLOGICALComparator: Quadrivalent Human Papillomavirus (HPV) vaccineQuadrivalent HPV vaccine was provided by the SPONSOR in single-dose vials containing a volume of 0.75 mL. The vaccine was administered as a 0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.
BIOLOGICALComparator: Menactra™ (Concomitant)A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Day 1
BIOLOGICALComparator: Adacel™ (Concomitant)a single administration of 0.5 mL intramuscular injection administered in a limb opposite that of quadrivalent HPV injection at Day 1
BIOLOGICALComparator: Menactra™ (Non-concomitant)A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1
BIOLOGICALComparator: Adacel™A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1

Timeline

Start date
2006-04-01
Primary completion
2007-04-01
Completion
2007-04-01
First posted
2006-05-12
Last updated
2015-03-12
Results posted
2009-07-13

Source: ClinicalTrials.gov record NCT00325130. Inclusion in this directory is not an endorsement.